BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27564672)

  • 1. Delivery of Alpha-1 Antitrypsin to Airways.
    Griese M; Scheuch G
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S346-51. PubMed ID: 27564672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
    McElvaney NG
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S191-6. PubMed ID: 27115956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
    Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
    Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
    Franciosi AN; McCarthy C; McElvaney NG
    Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency.
    Mordwinkin NM; Louie SG
    Expert Opin Pharmacother; 2007 Oct; 8(15):2609-14. PubMed ID: 17931094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route.
    Hubbard RC; Crystal RG
    Lung; 1990; 168 Suppl():565-78. PubMed ID: 2117165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An alpha 1-antitrypsin aerosol in the treatment of cystic fibrosis].
    Ferrer Calvete J; Aznar Lucea J; Morales Marín P; Pereda Pérez A; Llopis Carles R; Ribes Koninckx C; Ferrer González P; Marco Martínez V
    An Esp Pediatr; 1996 Feb; 44(2):109-11. PubMed ID: 8830566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.
    Geller DE; Kesser KC
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23 Suppl 1(Suppl 1):S55-9. PubMed ID: 20373910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-1 antitrypsin augmentation therapy.
    Wewers MD; Crystal RG
    COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
    Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
    Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting].
    Wilke A; Grohé C
    Pneumologie; 2013 Oct; 67(10):545-50. PubMed ID: 23999697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions.
    Hazari YM; Bashir A; Habib M; Bashir S; Habib H; Qasim MA; Shah NN; Haq E; Teckman J; Fazili KM
    Mutat Res Rev Mutat Res; 2017 Jul; 773():14-25. PubMed ID: 28927525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-1-antitrypsin and other proteinase inhibitors.
    Miravitlles M
    Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.
    Brand P; Schulte M; Wencker M; Herpich CH; Klein G; Hanna K; Meyer T
    Eur Respir J; 2009 Aug; 34(2):354-60. PubMed ID: 19251783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD.
    Stolk J; Tov N; Chapman KR; Fernandez P; MacNee W; Hopkinson NS; Piitulainen E; Seersholm N; Vogelmeier CF; Bals R; McElvaney G; Stockley RA
    Eur Respir J; 2019 Nov; 54(5):. PubMed ID: 31467115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
    Campos MA; Geraghty P; Holt G; Mendes E; Newby PR; Ma S; Luna-Diaz LV; Turino GM; Stockley RA
    Am J Respir Crit Care Med; 2019 Aug; 200(3):318-326. PubMed ID: 30965011
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
    Tonelli AR; Brantly ML
    Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism.
    Milger K; Holdt LM; Teupser D; Huber RM; Behr J; Kneidinger N
    Int J Chron Obstruct Pulmon Dis; 2015; 10():891-7. PubMed ID: 26005342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.